Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2007

OGT and Sanger Institute Work on a Test for Prenatal Syndromes

  • Oxford Gene Technology (OGT) and the Wellcome Trust Sanger Institute will develop a single-platform microarray to test for genetic defects in unborn children. The goal of is to develop and validate a microarray to specifically target a number of key prenatal syndromes.

    OGT will design and develop the  60-mer oligonucleotide microarray using its ink jet in situ synthesis platform and work. The company will work with the Sanger Institute’s clinical network to target the most appropriate syndromes.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »